A

Aurinia Pharmaceuticals
D

AUPH

11.880
USD
0.30
(2.56%)
مغلق
حجم التداول
49,792
الربح لكل سهم
1
العائد الربحي
-
P/E
28
حجم السوق
1,563,759,006
أصول ذات صلة الأخبار المقالات

العنوان: Aurinia Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmunediseases.